Alpha-1 antitrypsin deficiency (AA TD) is the major identified ge netic risk factor for chronic obstructive pulmonary disease (COPD). The biochemical events leading to lung destruction in AA TD are well understood, and most of our understanding of the pathoge nesis of COPD in general has been acquired through the study of AATD. There is a growing appreciation that early diagnosis of AATD can affect the course of disease and allow for appropriate treatment decisions to be made. Although there is published guidance regarding testing and treatment of AA TD, the impact of this guidance has been minimal. AATD is underdiagnosed, and the evidence for current treatment recommendations is not without co ntroversy. This article reviews the current recommendations for testing and treatment of AA TD. Some of these recommendations are expected to change as legislation to preven t genetic di scrimination is refi ned and new therapi es for this relatively common genetic predisposition are developed. Additional genetic modifiers ofCOPD wiU be found, and the path set by AA TD will facilitate their incorporation into our future management of COPD.
T he inherited condition ex-1 antitrypsin deficiency (AA TD) causes decreased plasma levels of the protein ex -I antitrypsin (AAT) as well as accumulation of misfolded AA T in the liver. Individuals with AA TD are at increased risk of de structive lung disease and liver injury, although many with AATD never develop clinically significant disease I Although more than 100 mutations of the AA T ge ne have been identified to date and approximately one third of those are linked with AA TD, the vast maj ority of identified deficient patients (more than 95%) have Z or S mutations 2 (see Nomenclature section). The inheritance of this co ndition is relatively straightforward ( Fig. 1) , although its expressio n, at least in terms of blood levels, is codominant rather than recessive.
Although co nsidered a rare condition by some, there arc ~20 million individuals in the United States who carry at least one abnormal AA T gene/ and the prevalence of homozygous AA TD (including complex heterozygotes like SZ) is at least 100,000 in the U.S. populati on,4 with a similar number in Europe. Only a fraction of those with AATD have been identified at this timc, and, although up to 3% of patients diagn oscd with COPD have AATD,s most of these remain undiagnosed. Efforts to increase detection have met with some success, but over 90% of individuals with AATD remain undiagnosed.
Editors, Gerard ]. Criner, M.D. and Bartolome R. Celli AAT is a very effective protease inhibitor, and it is almost unique in its ability to protect the protein elastin from degradation by serine proteases. 6 The most potent endogenous elastin degrad ing protease in humans is the elastase produced by the human neutrophilic leukocyte, human neutrophil elastase (HNE).' HNE is capable of degrading an array of different proteins in addition to elastin, but it is elastin degradation that leads to emphysema in humans. 8 At the alveolar level, AA T is the major inhibitor of HNE in the lungs, and its deficiency puts the lungs at increased risk of elastin destruction and emphysema progression. Detection of AATD has several advantages for those affected. Detecting an individual with AATD also detects a family at risk. The lung disease associated with AA TD, just as with more usual COPD, is treatable through the removal of risk factors, prevention and treatment of exacerbations, improvement of fitness and diet, symptom management, and provision of supplemental oxygen when indicated. 9 • 10 In addition, in appropriate individuals with lung disease due to AA TD, there is specific therapy that can slow or prevent additionallung injury.
There is guidance regarding testing for AA TD as well as recommendations regarding treatment. The evidence behind these recommendations is imperfect but growing. Exploring who to test and who to treat should improve the care of an important subgroup of individuals with COPD.
NOMENCLATURE
Historically, the mutations of the AA T gene and the proteins these genes produce have been named using letters of the alphabet. This dates back to the 1960s when AA T proteins were evaluated using po tato starch gel electrophoresis. II These gels were designed to migrate the AA T proteins so that the normal protein moved to the center of the gel while the most commonly identified deficient protein barely moved. The normal protein was labeled "M" and this d eficient protein was labeled "Z." As additional abnormal AA T proteins were identified, they were added to the list with their labels based on their migration in this gel system. Eventually, all the letters of the alphabet were used, and newly identified abnormal proteins were labeled according to their nearest neighbor in the gel with an added subscript usually representing the city of discovery, as in Mma lton .
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Isotypes of the normal M protein are now represented by subscript numerals, as in Mb M2J M 3 , and so forth. This nomenclature system has been called the protease inhibitor (PI) system. The various genes or their protein products are labeled in this system as PI Z or PI M, for example.
Finally, there is a group of mutations that lead to the production of no AAT protein or only fragments of AA T protein. 13 These arc the Null mutations and in the PI system are labeled as "0.: often followed by a number, even though there is no protein to migrate in a gel (see later discussion). Approximately 20 of these Null mutations have been found to date, and individuals unfortunate enough to have two Null mutations often develop emphysema at a very early age but have no protein accumulation in the liver and no apparent risk of liver disease.
HOW TO TEST
Recommendations regarding testing of individuals for AATD are complicated by the variety of testing methodologies available. There are three primary testing methods: (1) testing the blood to determine the quantity of AA T protein per volume (level testing), (2) testing the blood to evaluate the migration pattern of AA T protein in an isoe1ectric focusing gel between pH 4.0 and 5.0 (Pi-typing or phenotyping), and (3) evaluating an individual's DNA for common AAT mutations (genotyping). Each provides different information and often two or three tests are ordered on the same patient. 2 Level testing is certainly the least expensive and the most widely available. A severely deficient blood level (less than 50% of the lower limit of normal) provides clear evidence of . A.A . .TD. The issue with level testing is the information it does not provide. Level testing is poor at identifYing individuals carrying a single abnormal AA T gene because the level in AA T heterozygotcs can be close to or within the normal range. Level testing will not provide any information about the mutations involved, although individuals with severe deficiency are often assumed to have the Z mutation. Level testing will not identifY those with AA T mutations that lead to normal levels of a dysfunctional AA T protein, although these mutations appear to be extremely rare.
Pi-typing will identifY normal and abnormal AA T proteins of all types and is capable of detecting those 30 or so rare AATD-causing mutations, including those that lead to a dysfunctional protein. However, the preparation and interpretation of Pi-typing gels is as much an art as a science and requires the hands and eyes of experienced personnel. In addition, Pi-typing will not identify Null mutations because those mutations do not produce any circulating protein. Thus Pi-typing will not distinguish an individual with a ZNull genotype from one with a ZZ genotype.
Genotyping might be assumed to be the pre- 
WHOM TO TEST
Testing recommendations have changed over the years since AA TO was first described in 1963.
14 At the time of this initial description, AA TO was thought to be a disease of individuals with a family histoty of precocious emphysema. Sufferers were thought to develop emphysema as young adults, and their emphysema was destined to have a rapid downhill course. Thus testing was limited to those with a histoty of "familial emphysema."
A 1969 publication rsinted to AA TO as a cause of liver failure in infants. 5 Infants and children with otherwise unexplained liver disease were added to the list of those who should be tested for AATO.
A guidance document published in 1989. ' 
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The more difficult treatment decisions are those surrounding the lung disease of AATD. In countries where it is approved, augmentation therapy is often considered. Augmentation therapy, the intravenous administration of purified, concentrated, human plasmaderived AA T protein, usually on a weekly basis, raises the blood and lung levels of AAT. The expectation is that increasing the available normal AA T protein in the blood and lung will slow or halt the progression oflung disease in those with emphysema due to AATD.
Before any consideration of augmentation therapy, other risk factors for disease progression need to be eliminated. Most importantly, personal tobacco smoking and exposure to secondhand smoke need to be eliminated. Occupational exposures to dusts, smokes, and fumes should be reduced or eliminated. Only when lung disease continues to progress following the elimination of such risk factors should augmentation therapy be considered, although the documentation of such progression can be problematic.
The initial evaluation of augmentation therapy relied on measurement of AAT protein levels in blood and bronchoalveolar lavage as the end point of clinical trials.'o.>! Clinical efficacy could not be studied because of the small number of AATD patients identified in those days (early 1980s) and the long duration of observation required (3 to 5 years). Still, regulatory authorities in the United States and several European countries approved the marketing of augmentation therapy based on its biochemical rationale. In countries where it is approved, augmentation has become the standard of care for individuals with emphysema due to AATD. Because its effects are essentially prophylactic in nature, augmentation therapy was considered for all individuals with AATD, including those without any lung disease. This approach was discarded because (1) many individuals with AA TD will never develop lung disease, (2) augmentation therapy is a blood product and therefore has potential adverse effects and limited supply, and (3) Subsequent studies, including a recent meta-analysis, have tended to confirm these initial results. 24 Although much has been made of the significance of the initial FEV l values in making treatment decisions, it should be recalled that these were not randomized trials, and the numbers of subjects at the extremes of pulmonary function were small. It is well described that the rate of decline of lung function in COPD patients tends to decrease as severity increases, making improvements in rate of decline more difficult to measure in the most severe group. Those whose lung function was in the midrange of severity, where the most significant improvements were seen, passed through milder levels of obstruction on their way to . this moderately obstructed group. Should therapy be denied to individuals with mild emphysema due to AA TD to watch them develop more severe emphysema so that therapy can be initiated?
To date, there has not been a definitive, randomized, masked, placebo-controlled, well~owered clinical efficacy trial of augmentation therapy. This makes it difficult to accept augmentation therapy as having proven efficacy. However, the preponderance of evidence collected has documented the benefits of augmentation therapy. In contrast, the cost-benefit analyses of these data have documented the great expense of life-years saved. 26 The benefits of detection go beyond decisions regarding augmentation therapy, however. Education about AATD, including a broad understanding of disease mechanisms and risk, can help newly diagnosed patients obtain appropriate follow-up and treatment of their medical conditions. Family testing combined with genetic counseling can help an entire family avoid risk factors and monitor for disease. As additional genetic modifiers of COPD risk are identified, AA TD will be viewed as the model system, and its testing and treatment guidelines may find even wider application.
CONCLUSIONS

